Advanced search

Vol 80, No 2 (2022)
Review paper
Published online: 2022-02-28

open access

View PDF Download PDF file View HTML
Page views 6128
Article views/downloads 1410
Get Citation

Connect on Social Media

Connect on Social Media

Optimal anticoagulation in patients with atrial fibrillation and bioprosthetic heart valves

Roberta Bottino1, Andreina Carbone1, Biagio Liccardo1, Egidio Imbalzano2, Antonello D’Andrea3, Vincenzo Russo1
DOI: 10.33963/KP.a2022.0051
Pubmed: 35235996
Kardiol Pol 2022;80(2):137-150.

Abstract

The antithrombotic management of patients after surgical or transcatheter bioprosthetic heart valves (BHVs) replacement is still challenging. Our review aims to describe the current evidence on the best antithrombotic strategy among patients undergoing BHVs replacement (surgical or transcatheter) and/or valve repair, with particular attention to those with atrial fibrillation.

Keywords: anticoagulationantithrombotic therapybioprosthetic valvesatrial fibrillation

Full content:

View HTML View PDF Download PDF file

References

  1. Nkomo V, Gardin J, Skelton T, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006; 368(9540): 1005–1011.
    CrossRefPubMed
  2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
    CrossRefPubMed
  3. Heidenreich PA, Estes NA, Fonarow GC, et al. 2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2021; 77(3): 326–341.
    CrossRefPubMed
  4. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43(7): 561–632.
    CrossRefPubMed
  5. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143(5): e72–e7e227.
    CrossRefPubMed
  6. Russo V, Attena E, Mazzone C, et al. Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study. Clin Ther. 2019; 41(8): 1598–1604.
    CrossRefPubMed
  7. Russo V, Attena E, Di Maio M, et al. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. J Thromb Thrombolysis. 2020; 49(1): 42–53.
    CrossRefPubMed
  8. Russo V, Attena E, Di Maio M, et al. Non-vitamin K vs vitamin K oral anticoagulants in patients aged > 80 year with atrial fibrillation and low body weight. Eur J Clin Invest. 2020; 50(11): e13335.
    CrossRefPubMed
  9. Russo V, Carbone A, Rago A, et al. Direct oral anticoagulants in octogenarians with atrial fibrillation: it is never too late. J Cardiovasc Pharmacol. 2019; 73(4): 207–214.
    CrossRefPubMed
  10. Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017; 8(2): 67–75.
    CrossRefPubMed
  11. Durães AR, de Souza Roriz P, de Almeida Nunes B, et al. Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D. 2016; 16(2): 149–154.
    CrossRefPubMed
  12. Piepiorka-Broniecka M, Michalski TA, Figatowski T, et al. NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement. Cardiol J. 2021 [Epub ahead of print].
    CrossRefPubMed
  13. Guimarães HP, Lopes RD, de Barros E Silva PGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020; 383(22): 2117–2126.
    CrossRefPubMed
  14. Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021; 385(23): 2150–2160.
    CrossRefPubMed
  15. Anti-Thrombotic Strategy to Lower All cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis. American College of Cardiology. Available online: www.acc.org/latest-in-cardiology/clinical-trials/2021/05/14/01/58/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2fclinical-trials%2f2021%2f05%2f14%2f01%2f58%2fatlantis. (Access: February 4, 2022).
  16. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995; 25(5): 1111–1119.
    CrossRefPubMed
  17. Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart. 2007; 93(1): 137–142.
    CrossRefPubMed
  18. Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol. 2008; 51(12): 1203–1211.
    CrossRefPubMed
  19. Butnaru A, Shaheen J, Tzivoni D, et al. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol. 2013; 112(9): 1439–1444.
    CrossRefPubMed
  20. Brueck M, Kramer W, Vogt P, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg. 2007; 32(1): 108–112.
    CrossRefPubMed
  21. Aramendi JI, Mestres CA, Mestres CA, et al. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg. 2005; 27(5): 854–860.
    CrossRefPubMed
  22. R: The R Project for Statistical Computing. Available online: www.r-project.org/ (Access: January 3, 2022).
  23. Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg. 2005; 129(5): 1024–1031.
    CrossRefPubMed
  24. Moinuddeen L, Quin J, Shaw R, et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation. 1998; 98(19 Suppl): 95–98.
    PubMed
  25. Brennan J, Edwards F, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients. J Am Cardiol Coll. 2012; 60(11): 971–977.
    CrossRef
  26. Rafiq S, Steinbrüchel DA, Lilleør NB, et al. Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial. Thromb Res. 2017; 150: 104–110.
    CrossRefPubMed
  27. Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012; 308(20): 2118–2125.
    CrossRefPubMed
  28. Hudec V, Bena M, Artemiou P, et al. Reversible thrombotic mitral valve stenosis after transcatheter mitral valve replacement (TMVR): Is life-long anticoagulation therapy necessary? J Card Surg. 2017; 32(3): 190–192.
    CrossRefPubMed
  29. Eng MH, Greenbaum A, Wang DD, et al. Thrombotic valvular dysfunction with transcatheter mitral interventions for postsurgical failures. Catheter Cardiovasc Interv. 2017; 90(2): 321–328.
    CrossRefPubMed
  30. Pagnesi M, Moroni F, Beneduce A, et al. Thrombotic risk and antithrombotic strategies after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019; 12(23): 2388–2401.
    CrossRefPubMed
  31. Leon MB, Smith CR, Mack M, et al. PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010; 363(17): 1597–1607.
    CrossRefPubMed
  32. Leon M, Smith C, Mack M, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. New Engl J Med. 2016; 374(17): 1609–1620.
    CrossRefPubMed
  33. Baumgartner H, Falk V, Baumgartner H, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
    CrossRefPubMed
  34. Poliacikova P, Cockburn J, de Belder A, et al. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation — comparison of regimes. J Invasive Cardiol. 2013; 25(10): 544–548.
    PubMed
  35. Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2014; 113(2): 355–360.
    CrossRefPubMed
  36. D'Ascenzo F, Benedetto U, Bianco M, et al. Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI. EuroIntervention. 2017; 13(12): e1392–e1400.
    CrossRefPubMed
  37. Ichibori Y, Mizote I, Maeda K, et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. Aspirin alone. Circ J. 2017; 81(3): 397–404.
    CrossRefPubMed
  38. Mangieri A, Jabbour RJ, Montalto C, et al. Single-Antiplatelet therapy in patients with contraindication to dual-antiplatelet therapy after transcatheter aortic valve implantation. Am J Cardiol. 2017; 119(7): 1088–1093.
    CrossRefPubMed
  39. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011; 108(12): 1772–1776.
    CrossRefPubMed
  40. Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv. 2017; 10(13): 1357–1365.
    CrossRefPubMed
  41. Brouwer J, Nijenhuis VJ, Rodés-Cabau J, et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019; 105(10): 742–748.
    CrossRefPubMed
  42. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017; 389(10087): 2383–2392.
    CrossRefPubMed
  43. Ball K, Covington EW. Safety and efficacy of apixaban following bioprosthetic valve replacements: a retrospective evaluation. J Pharm Technol. 2021; 37(4): 193–201.
    CrossRefPubMed
  44. Pasciolla S, Zizza LF, Le T, et al. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig. 2020; 40(9): 839–845.
    CrossRefPubMed
  45. Shim CY, Seo J, Kim YJ, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. J Thorac Cardiovasc Surg. 2021 [Epub ahead of print].
    CrossRefPubMed
  46. Dangas GD, De Backer O, Windecker S, et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020; 382(2): 120–129.
    CrossRefPubMed
  47. Philippart R, Brunet-Bernard A, Clementy N, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 2016; 115(5): 1056–1063.
    CrossRefPubMed
  48. Yadlapati A, Groh C, Malaisrie SC, et al. Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol. 2016; 105(3): 268–272.
    CrossRefPubMed
  49. Russo V, Attena E, Mazzone C, et al. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience. Semin Thromb Hemost. 2018; 44(4): 364–369.
    CrossRefPubMed
  50. Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
    CrossRefPubMed
  51. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992.
    CrossRefPubMed
  52. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
    CrossRefPubMed
  53. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.
    CrossRefPubMed
  54. Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017; 135(13): 1273–1275.
    CrossRefPubMed
  55. Guimarães PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clin Cardiol. 2019; 42(5): 568–571.
    CrossRefPubMed
  56. Russo V, Carbone A, Attena E, et al. Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther. 2019; 41(12): 2549–2557.
    CrossRefPubMed
  57. Duan L, Doctor JN, Adams JL, et al. Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. Am J Cardiol. 2021; 146: 22–28.
    CrossRefPubMed
  58. Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2016; 9(16): 1706–1717.
    CrossRefPubMed
  59. Geis NA, Kiriakou C, Chorianopoulos E, et al. Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2017; 12(17): 2058–2066.
    CrossRefPubMed
  60. Kosmidou I, Liu Y, Alu MC, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. JACC Cardiovasc Interv. 2019; 12(16): 1580–1589.
    CrossRefPubMed
  61. Brouwer J, Nijenhuis VJ, Rodés-Cabau J, et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019; 105(10): 742–748.
    CrossRefPubMed
  62. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019; 12(16): 1566–1576.
    CrossRefPubMed
  63. Seeger J, Gonska B, Rodewald C, et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv. 2017; 10(1): 66–74.
    CrossRefPubMed
  64. Kawashima H, Watanabe Y, Hioki H, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR. JACC Cardiovasc Interv. 2020; 13(22): 2587–2597.
    CrossRefPubMed
  65. Butt JH, De Backer O, Olesen JB, et al. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021; 7(1): 11–19.
    CrossRefPubMed
  66. Melillo E, Carbone A, Rago A, et al. Update on Direct Oral Anticoagulants in Atrial Fibrillation Patients Undergoing Cardiac Interventional Procedures: From Clinical Trials to Real-World Evidence. J Cardiovasc Pharmacol. 2020; 75(3): 185–199.
    CrossRefPubMed
  67. Lacy SC, Saint Croix GR, Porter K, et al. Direct oral anticoagulants in patients with atrial fibrillation and bioprosthetic valve replacement: A meta-analysis. Catheter Cardiovasc Interv. 2021; 98(7): E1007–E1016.
    CrossRefPubMed
  68. Malik AH, Yandrapalli S, Aronow WS, et al. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart. 2019; 105(18): 1432–1436.
    CrossRefPubMed
  69. Kheiri B, Przybylowicz R, Simpson TF, et al. Meta-analysis of direct oral anticoagulants in patients with atrial fibrillation and bioprosthetic valves. Am J Cardiol. 2021; 142: 140–141.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Polish Heart Journal (Kardiologia Polska)

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice